Phase 3 Study Weighs Benefits of Standard Drugs Plus Surgery or Radiation Therapy

Phase 3 Study Weighs Benefits of Standard Drugs Plus Surgery or Radiation Therapy
The first patients have been enrolled in a Phase 3 clinical trial to evaluate if combining either prostate removal surgery or radiation therapy with standard systemic therapy delays cancer progression and improves survival of patients with advanced prostate cancer that has spread to other parts of the body. Enrollment has begun at the LSU Health New Orleans Scott Cancer Center. The study is a multi-center open-label Phase 3 trial (NCT03678025) sponsored by the National Cancer Institute and the Southwest Oncology Group, which intends to enroll 1,273 patients at several centers across the U.S. Recruitment is open now for patients whose cancer has spread to distant parts
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *